We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Finnish Study Describes Activators of SIRT6 Gene

By LabMedica International staff writers
Posted on 17 Apr 2018
Print article
A team of Finnish researchers conducted a study to evaluate the differences in chemical features between inhibitors and activators of the cancer-related SIRT6 gene.

SIRT6 (Sirtuin 6) is a chromatin-associated enzyme that is required for normal base excision repair of DNA damage in mammalian cells. Deficiency of SIRT6 in mice leads to abnormalities that overlap with aging-associated degenerative processes. SIRT6 also promotes the repair of DNA double-strand breaks by the process of non-homologous end joining.

Flavonoids are polyphenolic secondary metabolites synthesized by plants and fungi with various pharmacological effects. Due to their many classes of biological activity, they have been studied extensively in drug development. Flavonoids have been shown to modulate the activity of a NAD+-dependent histone deacetylase, SIRT6. Since SIRT6 has been implicated in longevity, metabolism, DNA-repair, and inflammatory response reduction, it is an interesting target in inflammatory and metabolic diseases as well as in cancer.

Investigators at the University of Eastern Finland (Kuopio, Finland) reported in the March 7, 2018, online edition of the journal Scientific Reports that flavonoids could alter SIRT6 activity in a structure dependent manner. Catechin derivatives with galloyl moiety displayed significant inhibition potency against SIRT6 at 10 microMolar concentration. The most potent SIRT6 activator, cyanidin, belonged to the family of anthocyanidins, and produced a 55-fold increase in SIRT6 activity compared to the three to 10-fold increase for the others. Cyanidin was also found to significantly increase SIRT6 expression in human colon adenocarcinoma Caco-2 cells. Cyanidin also decreased the expression of the TWIST1 and GLUT1 cancer promoter genes in Caco-2 cells, while increasing the expression of the tumor suppressor FOXO3 gene in the cells.

Results from docking studies indicated possible binding sites for SIRT6 inhibitors and activators. Inhibitors likely attached in a manner that could disturb NAD+ binding. The putative activator-binding site was found next to a loop near the acetylated peptide substrate-binding site. In some cases, the activators changed the conformation of this loop suggesting that it might play a role in SIRT6 activation.

"The most interesting results of our study relate to cyanidin, which is an anthocyanin found abundantly in wild bilberry, blackcurrant, and lingonberry," said first author Dr. Minna Rahnasto-Rilla, pharmacology researcher at the University of Eastern Finland.

Related Links:
University of Eastern Finland

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.